SARS-CoV-2 nsp14-IN-10
SARS-CoV-2 nsp14-IN-10 is a highly potent and selective NSP14 (IC50 = 0.34 µM) S-adenosylmethionine (SAM) binding pocket inhibitor. SARS-CoV-2 nsp14-IN-10 demonstrates robust antiviral activity against SARS-CoV-2. SARS-CoV-2 nsp14-IN-10 exhibits broad-spectrum activity against other betacoronaviruses and inhibits SARS-CoV-2 at the replication stage. SARS-CoV-2 nsp14-IN-10 suppresses viral translation and exhibits immunostimulatory effects. SARS-CoV-2 nsp14-IN-10 specifically reverses NSP14-mediated alterations inhost transcriptome. SARS-CoV-2 nsp14-IN-10 can be used for the study of SARS-CoV-2.
For research use only. We do not sell to patients.
- Formula: C24H22F3N7O3S
- Molecular Weight:545.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
SARS-CoV-2 nsp14-IN-10 (Compound C10) (20-500 µM) specifically binds to the SAM recognition pocket of NSP14 (KD = 187 nM) in a competitive manner with SAM[1].
SARS-CoV-2 nsp14-IN-10 (5-25 μM, 8 h) enhances the thermostability of NSP14 protein in HEK293-NSP14 cells, indicating that it binds to the target in living cells[1].
SARS-CoV-2 nsp14-IN-10 (24 h) significantly reduces the infection rates of the original SARS-CoV-2 strain, Delta, and Omicron variants in A549-ACE2 cells (EC50 values of 0.31 μM, 0.50 μM and 0.06 μM, respectively)[1].
SARS-CoV-2 nsp14-IN-10 (10 µM, 24 h) potently inhibits the replication phase of SARS-CoV-2 in HeLa cells[1].
SARS-CoV-2 nsp14-IN-10 (3-20 μM, 0-24 h) shows strong inhibitory activity in A549-ACE2 cells infected with SARS-CoV-2 trVLP during both full-time and post-entry treatments, while entry treatment shows no significant inhibition[1].
SARS-CoV-2 nsp14-IN-10 (20-40 μM, 8 h) inhibits the translation initiation of SARS-CoV-2 mRNA in A549-ACE2 cells infected with trVLP, specifically by cap maturation, selectively impairing[1].
SARS-CoV-2 nsp14-IN-10 (20-40 µM, 8 h) selectively inhibits viral translation in A549-ACE2 cells infected with SARS-CoV-2 trVLP[1].
SARS-CoV-2 nsp14-IN-10 (20 μM, 24 h) significantly reduced the expression levels of Spike mRNA and protein in A549-ACE2 cells infected with SARS-CoV-2 trVLP[1].
SARS-CoV-2 nsp14-IN-10 (20 μM, 24 h) upregulates the expression of interferon-stimulated genes (ISGs) such as RSAD2, IFI6, and IRF7 in A549-ACE2 cells[1].
SARS-CoV-2 nsp14-IN-10 (5-20 μM, 48 h) reverses host transcriptome changes induced by NSP14 expression in HEK293-NSP14 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293-NSP14 cells
-
Concentration:5 μM, 10 μM, 15 μM, 20 μM, 25 μM
-
Incubation Time:8 h
-
Result:Enhanced the thermal stability of NSP14 protein.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:The six- to eight-week-old male K18-hACE2 transgenic mice (18-20 g) were inoculated intranasally with 5 × 103 focus-forming units of SARS-CoV-2 nCoV-SH01 strain[1].
-
Dosage:60 mg/kg, 120 mg/kg, 180 mg/kg
-
Administration:I.p., twice daily for 3 days
-
Result:120 mg/kg significantly reduced pulmonary viral titer.
60 mg/kg showed a decreasing trend, but the effect was not statistically significant.
Reduced alveolar wall thickening, congestion, and inflammatory infiltration.
The positive signal of the SARS-CoV-2 nucleocapsid protein was significantly reduced.
Chemical Information
-
Molecular Weight 545.54
-
Formula C24H22F3N7O3S
-
SMILES
O=C(NC1CCN(C2=C3N=CNC3=NC=N2)CC1)C4=CC=CC(NS(=O)(C5=CC=C(C(F)(F)F)C=C5)=O)=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SARS-CoV-2 nsp14-IN-10 Related Classifications
HY-179556 Related Classifications
Powered by Bioz